Xenon Pharmaceuticals (XENE) News Today $33.44 +2.04 (+6.50%) As of 04/14/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Purchased by Fmr LLCFmr LLC raised its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 8.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 7,525,290 shares of the biopharmaceutical company's stock after purchasing an additionalApril 13 at 5:25 AM | marketbeat.comFederated Hermes Inc. Sells 177,700 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Federated Hermes Inc. trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 24.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 558,500 shares of the biopharmaceutical company's stock afterApril 11, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Hits New 12-Month Low - What's Next?Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week Low - Should You Sell?April 10, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Up 5.2% - Here's What HappenedXenon Pharmaceuticals (NASDAQ:XENE) Trading 5.2% Higher - Here's WhyApril 10, 2025 | marketbeat.comADAR1 Capital Management LLC Purchases 22,644 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)ADAR1 Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 81.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 50,547 shares of the biopharmApril 9, 2025 | marketbeat.comExodusPoint Capital Management LP Has $2.70 Million Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)ExodusPoint Capital Management LP trimmed its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 73.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,884 shares of the biopharmaceApril 9, 2025 | marketbeat.comAtika Capital Management LLC Lowers Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Atika Capital Management LLC reduced its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 42.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,600 shares of the bioApril 8, 2025 | marketbeat.comFranklin Resources Inc. Boosts Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Franklin Resources Inc. grew its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 575,590 shares of the biopharmaceutical company's stock after purchaApril 8, 2025 | marketbeat.comAlliancebernstein L.P. Raises Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Alliancebernstein L.P. lifted its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,443,180 shares of the biopharmaceutical company's stock afterApril 7, 2025 | marketbeat.comJPMorgan Chase & Co. Increases Stock Holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)JPMorgan Chase & Co. grew its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 38.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,356,895 shares of the bApril 7, 2025 | marketbeat.comPrudential Financial Inc. Acquires 24,956 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Prudential Financial Inc. increased its holdings in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 177.7% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 39,000 shares of the biopharmaceuticalApril 7, 2025 | marketbeat.comRaymond James Financial Inc. Buys New Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Raymond James Financial Inc. purchased a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,331 shares ofApril 7, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Cut to "Sell" at StockNews.comApril 7, 2025 | americanbankingnews.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.comStockNews.com cut shares of Xenon Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Sunday.April 7, 2025 | marketbeat.comWellington Management Group LLP Sells 65,836 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Wellington Management Group LLP cut its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,777,611 shares of the biopharmaceutical companyApril 5, 2025 | marketbeat.comKLP Kapitalforvaltning AS Purchases Shares of 12,800 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)KLP Kapitalforvaltning AS acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 12,800 shares of the biopharmaceutical company's stock, valued at approximately $502April 5, 2025 | marketbeat.comXenon Pharmaceuticals Looks Attractive Before Epilepsy DataApril 4, 2025 | seekingalpha.comXenon Pharmaceuticals (NASDAQ:XENE) Sees Large Volume Increase - What's Next?Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Here's What HappenedApril 4, 2025 | marketbeat.comXenon Slides Ahead of San Diego ConcferenceApril 4, 2025 | baystreet.caXenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025April 4, 2025 | globenewswire.comInvestors Purchase Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) saw some unusual options trading on Wednesday. Traders bought 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the typical volume of 165 put options.April 4, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Stock Price Down 6.9% - Time to Sell?Xenon Pharmaceuticals (NASDAQ:XENE) Shares Down 6.9% - Here's WhyApril 3, 2025 | marketbeat.comXenon Pharmaceuticals Enters Oversold Territory (XENE)April 3, 2025 | nasdaq.comThrivent Financial for Lutherans Sells 12,394 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Thrivent Financial for Lutherans reduced its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 28.8% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,699 shares of the biopharmaApril 2, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by AnalystsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. Nine research analysts have rated the stock with a buy rating. The average 12 month targetApril 2, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Reaches New 52-Week Low - Time to Sell?Xenon Pharmaceuticals (NASDAQ:XENE) Sets New 1-Year Low - Should You Sell?April 1, 2025 | marketbeat.comDnB Asset Management AS Purchases 12,620 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)DnB Asset Management AS lifted its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 6.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,243 shares of the biopharmaceutical coMarch 31, 2025 | marketbeat.comPictet Asset Management Holding SA Reduces Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Pictet Asset Management Holding SA trimmed its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,496,511 shares of the biopharmaceuticMarch 31, 2025 | marketbeat.comStockNews.com Upgrades Xenon Pharmaceuticals (NASDAQ:XENE) to HoldStockNews.com raised Xenon Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday.March 30, 2025 | marketbeat.comLoomis Sayles & Co. L P Sells 20,077 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Loomis Sayles & Co. L P cut its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 687,145 shares of the biophMarch 29, 2025 | marketbeat.comBIT Capital GmbH Makes New Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)BIT Capital GmbH acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 53,928 shares of the biopharmaceutical company's stMarch 28, 2025 | marketbeat.comFox Run Management L.L.C. Has $338,000 Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Fox Run Management L.L.C. lessened its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 56.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,621 shares of the biopharmaMarch 27, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - Here's WhyXenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Down - What's Next?March 26, 2025 | marketbeat.comWhat is William Blair's Forecast for XENE Q1 Earnings?Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Stock analysts at William Blair issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a research report issued on Monday, March 17th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earningsMarch 20, 2025 | marketbeat.comXenon Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the recipient of unusually large options trading on Wednesday. Traders bought 4,063 put options on the stock. This is an increase of approximately 2,362% compared to the typical daily volume of 165 put options.March 20, 2025 | marketbeat.comXenon to Present at Stifel 2025 Virtual CNS ForumMarch 12, 2025 | financialpost.comXenon to Present at Stifel 2025 Virtual CNS ForumMarch 12, 2025 | globenewswire.comFMR LLC's Strategic Acquisition of Xenon Pharmaceuticals Inc. SharesMarch 7, 2025 | gurufocus.comCandriam S.C.A. Purchases 28,320 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)Candriam S.C.A. boosted its holdings in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 492,181 shares of theMarch 7, 2025 | marketbeat.comXenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Rating of "Buy" by BrokeragesXenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) has earned an average recommendation of "Buy" from the nine research firms that are currently covering the company, Marketbeat.com reports. Nine equities research analysts have rated the stock with a buy recommendation. The average twelve-March 7, 2025 | marketbeat.comTraders Buy Large Volume of Put Options on Xenon Pharmaceuticals (NASDAQ:XENE)Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Get Free Report) was the target of some unusual options trading on Wednesday. Investors acquired 4,063 put options on the stock. This represents an increase of approximately 2,362% compared to the average daily volume of 165 put options.March 6, 2025 | marketbeat.comFY2028 EPS Estimate for Xenon Pharmaceuticals Cut by AnalystXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Wedbush dropped their FY2028 earnings per share (EPS) estimates for shares of Xenon Pharmaceuticals in a research report issued to clients and investors on Friday, February 28th. Wedbush analyst L. Chico now expectsMarch 3, 2025 | marketbeat.comQ1 Earnings Forecast for XENE Issued By HC WainwrightXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - HC Wainwright issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, February 28th. HC Wainwright analyst D. Tsao expects that the biopharmaceutical company will post earnings per share of ($1.32) for theMarch 3, 2025 | marketbeat.comEquities Analysts Offer Predictions for XENE Q1 EarningsXenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for Xenon Pharmaceuticals in a report issued on Friday, February 28th. William Blair analyst M. Minter forecasts that the biopharmaceutical company will post earnings pMarch 3, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for XENE Q1 Earnings?Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for shares of Xenon Pharmaceuticals in a report released on Thursday, February 27th. Leerink Partnrs analyst M. Goodman forecasts that the biopharmaceMarch 3, 2025 | marketbeat.comXenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month Low - Time to Sell?Xenon Pharmaceuticals (NASDAQ:XENE) Reaches New 12-Month Low - Here's What HappenedMarch 1, 2025 | marketbeat.comXenon Pharmaceuticals' (XENE) "Outperform" Rating Reaffirmed at William BlairWilliam Blair reiterated an "outperform" rating on shares of Xenon Pharmaceuticals in a report on Friday.March 1, 2025 | marketbeat.comXenon Pharmaceuticals’ Earnings Call Highlights Progress and ChallengesMarch 1, 2025 | msn.comXenon Pharmaceuticals (NASDAQ:XENE) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPSXenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.89) by $0.05.February 28, 2025 | marketbeat.comXenon Pharmaceuticals Inc.: Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business UpdateFebruary 28, 2025 | finanznachrichten.de Remove Ads Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address XENE Media Mentions By Week XENE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XENE News Sentiment▼1.100.83▲Average Medical News Sentiment XENE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XENE Articles This Week▼94▲XENE Articles Average Week Remove Ads Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viatris News Qiagen News Ascendis Pharma A/S News Roivant Sciences News Lantheus News TG Therapeutics News Revolution Medicines News BridgeBio Pharma News Legend Biotech News Blueprint Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XENE) was last updated on 4/15/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts